Core Viewpoint - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is identified as one of the top 10 most shorted biotech stocks to consider for investment, with a price target increase from $21 to $22 by Wedbush analyst Laura Chico, who maintains an Outperform rating on the stock [1][2]. Financial Performance - For the fourth quarter, BioCryst reported an EPS of $1.12, a significant improvement from a loss of $0.13 in the same quarter of the previous year [3]. - The company achieved revenues of $406.5 million for the quarter, up from $131.5 million year-over-year [3]. Business Development - The CEO, Charlie Gayer, highlighted that 2025 was a transformative year for the company, marking its first full-year profitability driven by strong commercial execution and the highest level of new patient prescriptions for ORLADEYO since its launch [3]. - BioCryst completed the acquisition of Astria Therapeutics, which is expected to enhance its hereditary angioedema (HAE) portfolio and support long-term growth [3]. Product Pipeline - BioCryst focuses on developing treatments for rare and hard-to-treat diseases, with significant products aimed at managing influenza and hereditary angioedema [4]. - The company is also advancing several promising new medicines in clinical trials in collaboration with major pharmaceutical partners [4].

BioCryst Pharmaceuticals FY Conference Summary Company Overview - **Company**: BioCryst Pharmaceuticals (NasdaqGS: BCRX) - **Key Products**: ORLADEYO, navenibart - **Recent Acquisition**: Astria Therapeutics Financial Performance - **2025 Revenue**: $601 million from ORLADEYO, $563 million after excluding European business sale - **Operating Profit**: $214 million non-GAAP operating profits - **2026 Guidance**: $625 million to $645 million, representing a 13% growth over the previous year [4][28] Product Insights ORLADEYO - **Launch Dynamics**: - ORLADEYO is the only oral prophylactic treatment on the market, differentiating it from injectables [12] - Approximately 50% of patients switching to ORLADEYO are coming from injectable therapies [12] - 60% of patients who try ORLADEYO remain on it after one year [8] - **Super-Responders**: - Over 50% of clinical trial participants remained on ORLADEYO for two years, showing a 91% reduction in attacks [7] - Patients prefer oral administration, leading to high retention rates among super-responders [34] - **Pediatric Launch**: - Approval for pediatric use in December, with expectations of significant adoption due to the convenience of ORLADEYO pellets [20] - Current pediatric treatment is underdiagnosed and undertreated, with only 40% of diagnosed children receiving prophylaxis [19] Navenibart - **Acquisition Rationale**: - Navenibart offers a long-acting injectable option, requiring only 2-4 injections per year, which is appealing to patients currently on more frequent injectable therapies [45] - Phase 1b/2 data shows a 92% reduction in attacks for 3-month dosing and 90% for 6-month dosing [46] - **Market Positioning**: - Navenibart is expected to attract patients currently satisfied with injectables due to its efficacy and reduced injection frequency [47] - The product is anticipated to launch within the existing BioCryst portfolio, leveraging established patient loyalty [58] Market Dynamics - **Patient Growth**: - The number of diagnosed HAE patients is growing at approximately 3% annually, with significant potential for further diagnosis and treatment [60] - Current estimates suggest around 1,100 pediatric patients should be diagnosed, with many still untreated [19][61] - **Competitive Landscape**: - The market is becoming increasingly competitive with new entrants, but BioCryst's established presence and patient loyalty provide a competitive edge [56] Future Outlook - **Long-Term Projections**: - BioCryst anticipates a revenue growth rate in the mid-teens through the 2030s, supported by strong patent protection for both ORLADEYO and navenibart [63] - The company is focused on maintaining operational efficiency without the need for additional sales or marketing teams for navenibart [64] - **Pipeline Developments**: - Ongoing studies for KLK5 inhibitor for Netherton's disease, with results expected by year-end [65][68] - Plans to enhance market-building activities upon successful drug development [72] Key Risks and Considerations - **Guidance Caution**: - The 2026 guidance is considered conservative due to the absence of last year's Medicare payer tailwinds and the sale of the European business [28][29] - **Market Adoption Uncertainty**: - The speed of pediatric adoption and the overall market response to navenibart remain uncertain [22][27] Conclusion - BioCryst Pharmaceuticals is positioned for growth with its unique product offerings and strategic acquisitions, although it faces challenges in market dynamics and patient adoption rates. The company’s focus on maintaining a strong pipeline and leveraging existing patient relationships will be crucial for its future success.

Core Insights - BioCryst Pharmaceuticals received FDA approval for ORLADEYO oral pellets for children aged 2 to less than 12 in December 2025, addressing a significant unmet need in hereditary angioedema (HAE) treatment [1] - The company reported strong financial performance for 2025, with ORLADEYO revenue reaching $601.8 million, a 38% increase year-over-year, and expects continued growth in 2026 [3][4] - BioCryst is advancing its pipeline, including navenibart, which is in pivotal Phase 3 trials, and BCX17725 for Netherton syndrome, with promising early results [6][10] Financial Performance - ORLADEYO revenue for 2025 was $601.8 million, up 38% year-over-year, and 43% when excluding the European business sold in October [3][4] - Non-GAAP operating profit rose to $214 million, a 198% increase year-over-year, marking the highest in company history [13] - The company ended 2025 with $337.5 million in cash and investments and entered a $400 million financing facility with Blackstone Life Sciences [14] Product Development and Pipeline - Navenibart is currently enrolling in the Phase 3 Alpha Orbit trial, targeting approximately 145 patients by mid-2026, with a BLA submission expected after mid-2027 [4][6] - Phase 2 data for navenibart showed significant attack-rate reductions, with mean reductions of 90-92% [7] - The company is also advancing BCX17725 for Netherton syndrome, with completed Phase 1 trials showing safety and tolerability [10][11] Market Positioning and Strategy - BioCryst views the HAE market as "structurally segmented," emphasizing that treatment choices are driven by patient needs rather than a single efficacy leader [3] - The pediatric launch of ORLADEYO is included in 2026 guidance but is expected to be a small contributor in the near term [5] - The company implemented a 9% price increase for ORLADEYO in January, expecting to net about half of that increase [15]

Summary of Pharvaris FY Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Treatment of Hereditary Angioedema (HAE), a rare genetic condition characterized by painful and potentially fatal swelling attacks [4][5] Core Points and Arguments Company Background - Pharvaris was established 10 years ago, with a focus on addressing unmet needs in HAE treatment, particularly for an oral therapy option [4][6] - The company aims to develop deucrictibant, an oral B2 receptor antagonist, to provide a highly efficacious treatment for HAE and other forms of angioedema [7][8] Market Dynamics - The current market for HAE treatments is dominated by injectables, with approximately 63% of patients on long-term prophylaxis, representing about 80% of the market value [12][13] - The clinical guidelines suggest that ideally, HAE patients should never suffer from attacks, highlighting the need for effective prophylactic treatments [13] Clinical Data - The Phase 3 trial for deucrictibant in the on-demand setting showed significant results, with a primary endpoint met and all 11 secondary endpoints achieving statistical significance [16] - Key findings include: - Onset of symptom relief at 1.28 hours compared to 12 hours for placebo [17] - End of progression of the attack at 17 minutes, providing comfort to patients [17] - Faster complete resolution compared to standard care and recently approved oral therapies [19] Competitive Landscape - The oral therapy market is becoming increasingly competitive, with KalVista's EKTERLY recently launched. However, deucrictibant is positioned to differentiate itself through faster onset and resolution of symptoms [21][22] - The Phase 2 data for deucrictibant in the prophylactic setting showed an 84.5% attack reduction, comparable to injectable therapies [41] Regulatory and Commercial Strategy - Pharvaris plans to file for NDA in the first half of 2026, with a potential launch about a year later [20] - The company is expanding its Phase 3 studies to include a broader patient demographic and geographic range, which may mitigate risks associated with trial outcomes [45] Financial Outlook - The company has sufficient cash runway into the first half of 2027, with plans to ramp up commercial operations and team expansion [56][57] Additional Important Information - Pharvaris will present at the QUAD A conference, showcasing Phase 3 data and other significant findings, including a 92.3% attack reduction from an open-label extension study [53] - The company is also involved in community engagement, sponsoring events like the HAEA Foundation's 5K run [54] This summary encapsulates the key points discussed during the Pharvaris FY conference call, highlighting the company's strategic focus, clinical advancements, market positioning, and financial outlook.

Full Year 2025 Results Call Corporate Update & Financial Results February 26, 2026 CONFIDENTIAL & PROPRIETARY Forward-looking statements This presentation contains forward-looking statements, including statements regarding, among other things, future results, performance or achievements, expectations regarding pipeline development, anticipated approval and commercialization of navenibart, pharmaceutical research and development, such as drug discovery, preclinical and clinical development activities and rel ...

Core Insights - BioCryst is undergoing significant transformation and is positioned for exciting developments in the near future [1] Company Performance - The company reported substantial growth in new patient prescriptions for ORLADEYO in 2025, marking a pivotal year for BioCryst [2]

BioCryst Pharmaceuticals FY Conference Summary Company Overview - **Company**: BioCryst Pharmaceuticals (NasdaqGS: BCRX) - **Event**: FY Conference held on January 12, 2026 - **Key Speakers**: Charlie Gayer (CEO), Babar Ghias (CFO), Dr. Bill Sheridan (Chief Development Officer) Core Industry and Company Insights Industry: Rare Disease Pharmaceuticals - BioCryst focuses on developing treatments for rare diseases, particularly hereditary angioedema (HAE) Key Developments in 2025 - **ORLADEYO Growth**: Achieved the highest number of new patient prescriptions in the U.S. since its launch, with a paid rate improvement ending Q1 at 84% and the year at 81% compared to a long-term goal of 85% [3][4] - **European Business Sale**: Sold the European business for $250 million to streamline operations and focus on U.S. growth [3][4] - **Profitability**: Achieved profitability for the first time in company history, with expectations to maintain profitability moving forward [4] - **New Approval**: Received approval for ORLADEYO for children as young as two years old, expanding the market potential [4] Financial Performance - **2025 Preliminary Results**: - ORLADEYO revenue: $601 million, exceeding guidance of $590-$600 million - Ongoing business revenue (excluding European business): $563 million - Cash position: Nearly $340 million [5] - **2026 Revenue Guidance**: Anticipating ORLADEYO revenue of $625-$645 million and total revenue (including RAPIVAB) of $635-$660 million [5] Growth Strategy - **Three Pillars for Growth**: 1. **ORLADEYO**: Expected to reach $1 billion in peak sales by 2029 with a contribution margin over 80% [6] 2. **Novanavart**: Acquired through Astria Therapeutics, expected to enhance the portfolio with a differentiated injectable product [4][12] 3. **Netherton Syndrome Program**: Aiming to develop a transformative therapy for a high-need rare disease with no current treatments [20][21] Market Dynamics - **HAE Market**: Competitive landscape with 10-11 approved products, but ORLADEYO remains the only oral prophylaxis option, which is a significant differentiator [28][29] - **Patient Retention**: Approximately 50% of patients remain on ORLADEYO after five years, indicating strong efficacy and satisfaction [9] Future Outlook - **Revenue Growth**: Projected 15% year-over-year CAGR for ORLADEYO through 2029, with additional contributions from Novanavart and international markets [11][30] - **Acquisition of Astria**: Expected to close soon, enhancing BioCryst's capabilities in the HAE space [12][26] - **Netherton Syndrome**: Initial proof of concept trial expected to provide data by the end of 2026, with potential for pivotal study thereafter [26][43] R&D and Pipeline - **BCX 17725 for Netherton Syndrome**: Entering initial proof of concept trials, with a focus on safety and efficacy in patients [20][24] - **Avoralstat for Diabetic Macular Edema**: Currently in phase 1 study, with plans to out-license post-study completion [31][48] Conclusion - BioCryst Pharmaceuticals is positioned for significant growth in the rare disease market, with a strong focus on innovative therapies and strategic acquisitions. The company aims to leverage its successful commercialization strategies and maintain profitability while expanding its product offerings.

Financial Performance and Outlook - BioCryst achieved its first full year of profitability in 2025[13] - Preliminary ORLADEYO revenue for 2025 reached $601 million, with $563 million excluding European revenue[14] - The company anticipates ORLADEYO revenue between $625 million and $645 million in 2026[14] - Total revenue for 2026 is projected to be in the range of $635 million to $660 million[14] - Non-GAAP operating expenses for 2026 are expected to be between $380 million and $390 million, and $450 million to $470 million including the Astria acquisition[14] - BioCryst expects to have a cash balance of over $1 billion by 2029[37,52] Strategic Initiatives and Pipeline - BioCryst is acquiring Astria Therapeutics for approximately $700 million TEV to strengthen its HAE portfolio with navenibart[35] - ORLADEYO has a sustainable peak revenue opportunity of $1 billion, with IP protection extending into 2040[20] - The company received FDA approval for ORLADEYO pellet formulation for pediatric patients aged 2 to under 12 with HAE[13] - BCX17725 is being developed as a targeted KLK5 inhibitor for Netherton syndrome, with Phase 1 data from Part 4 expected by the end of 2026[54,69]

Core Insights - BioCryst is experiencing significant revenue growth from its product ORLADEYO, with current revenues between $590 million and $600 million, projected to peak at $1 billion [3] - The company has a strong patent protection for ORLADEYO extending to 2040, which supports its growth trajectory [3] - BioCryst has a pipeline that includes two clinical candidates: 17725 for Netherton syndrome and avoralstat for DME [3] - The company is in a favorable financial position, having proposed an acquisition of Astria [4]

Summary of BioCryst Pharmaceuticals Conference Call Company Overview - **Company**: BioCryst Pharmaceuticals (NasdaqGS:BCRX) - **Key Products**: ORLADEYO, Nevenabart - **Revenue**: ORLADEYO revenue projected between $590-$600 million, with a peak potential of $1 billion by 2029 [3][10] Core Points and Arguments ORLADEYO Performance - ORLADEYO is the only oral drug in the market for HAE, showing strong demand despite new competitors [6] - The company expects continued growth in Q4, maintaining revenue guidance of $590-$600 million for the year [6] - The peak sales guidance for ORLADEYO remains at $1 billion, now including pediatric sales and excluding EU sales [10] EU Divestiture - BioCryst divested its EU business for $250 million, which was previously break-even with $50 million in revenue [8] - The divestiture allows for a cleaner balance sheet and supports the acquisition of Astria [9] Astria Acquisition - The acquisition of Astria is expected to close in Q1 2026, enhancing BioCryst's portfolio with Nevenabart, an injectable therapy for HAE [14][40] - Nevenabart is positioned as a differentiated product with a favorable dosing schedule compared to existing therapies [17][28] Market Dynamics - The HAE market is evolving, with 80% of patients on prophylactic therapy, creating a competitive landscape for new entrants [12] - There are approximately 8,000 potential patients who have not yet tried ORLADEYO, indicating significant growth opportunities [11] Pediatric Opportunity - A PDUFA date for pediatric indications is set for December 12, with expectations for pricing to be equivalent to capsules [32] - The pediatric formulation will include four different granule presentations [32] Netherton Syndrome - BioCryst is developing a treatment for Netherton syndrome, with data updates expected in Q1 2026 [34] - The market opportunity is significant, with an identified patient population of 1,600, which is expected to grow as therapies become available [37] Financial Outlook - The company has lowered its expense guidance to $430-$440 million, indicating improved operational efficiency [39] - BioCryst anticipates continued profitability and cash flow positivity, with operating expenses expected to decrease post-Astria acquisition [40] Additional Important Points - The company is focused on maintaining a strong prescriber base and generating real-world evidence to support ORLADEYO's efficacy [13] - BioCryst's strategy includes leveraging existing infrastructure to minimize costs associated with launching Nevenabart [22] - The company is exploring business development opportunities that do not necessarily need to be blockbuster drugs but can still provide significant bottom-line benefits [41] This summary encapsulates the key insights from the BioCryst Pharmaceuticals conference call, highlighting the company's strategic direction, product performance, and market opportunities.